ANN ARBORMany medically minded researchers are in hot pursuit of designs that will allow drug-carrying nanoparticles to navigate tissues and the interiors of cells, but University of Michigan engineers have discovered that these particles have another hurdle to overcome: escaping the bloodstream.
Drug delivery systems promise precision targeting of diseased tissue, meaning that medicines could be more effective at lower doses and with fewer side effects. Such an approach could treat plaques in arteries, which can lead to heart attacks or strokes.
Drug carriers would identify inflamed vessel walls and deliver a drug that removes the deposits of calcium, cholesterol and other substances. Or, the carriers might seek out markers of cancer and kill off the small blood vessels in tumors, starving the malignant tissue of food and oxygen.
Nanoparticles, which have diameters under one micron, or one-thousandth of a millimeter, are thought to be the most promising drug carriers. Omolola Eniola-Adefeso, U-M professor of chemical engineering who studies nanoparticles in flowing blood, says the immune system can't get rid of them quickly.
"It's hard for a white blood cell to understand it has a nanoparticle next to it," she said.
Those same tiny dimensions allow them to slip through the cracks between cells and infiltrate cell membranes, where they can go to work administering medicine. But Eniola-Adefeso and her team found that these particles have an Achilles heel.
Blood vessels are the body's highways, and once nanoparticles get into the flow, they find it very difficult to reach the exits. In all vessels other than capillaries, the red cells in flowing blood tend to come together in the center.
"The red blood cells sweep those particles that are less than one micron in diameter and sandwich them," she said.
Trapped among the red cells, the nanoparticles can't reach the vessel wall to treat di
|Contact: Kate McAlpine|
University of Michigan